Literature DB >> 34765690

Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism.

Ghalia Al-Kasbi1, Abeer Al-Saegh1,2, Ahmed Al-Qassabi3, Tariq Al-Jabry1, Fahad Zadjali4, Said Al-Yahyaee1, Almundher Al-Maawali1.   

Abstract

BACKGROUND: PTRHD1 was proposed as a disease-causing gene of intellectual disability, spasticity, and parkinsonism.
OBJECTIVES: To characterize the clinical phenotype and the molecular cause of intellectual disability in four affected individuals of a consanguineous family.
METHODS: Clinical evaluation, whole-exome sequencing, Sanger sequencing, reverse transcription polymerase chain reaction (PCR), real-time PCR, immunoblot, and isoelectric focusing.
RESULTS: A homozygous 28-nucleotide frameshift deletion introducing a premature stop codon in the PTRHD1 exon 1 was identified in the four affected members. We further confirmed the apparent transcript escape of the nonsense-mediated messenger RNA (mRNA) decay pathway. Real-time PCR showed that mRNA expression of the mutant PTRHD1 is higher compared to the wild-type. Western blotting and isoelectric focusing identified a truncated, but stable mutant PTRHD1 protein expressed in the patient's primary cells.
CONCLUSIONS: We provide further evidence that PTRHD1 mutations are associated with autosomal-recessive childhood-onset intellectual disability associated with spasticity and parkinsonism.
© 2021 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  PTRHD1; intellectual disability; parkinsonism

Year:  2021        PMID: 34765690      PMCID: PMC8564806          DOI: 10.1002/mdc3.13342

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


  7 in total

1.  PTRHD1 Loss-of-function mutation in an african family with juvenile-onset Parkinsonism and intellectual disability.

Authors:  Demy J S Kuipers; Jonathan Carr; Soraya Bardien; Pearl Thomas; Boiketlo Sebate; Guido J Breedveld; Rick van Minkelen; Rutger W W Brouwer; Wilfred F J van Ijcken; Marjon A van Slegtenhorst; Vincenzo Bonifati; Marialuisa Quadri
Journal:  Mov Disord       Date:  2018-11-06       Impact factor: 10.338

2.  Orthologs of a novel archaeal and of the bacterial peptidyl-tRNA hydrolase are nonessential in yeast.

Authors:  Guillermina Rosas-Sandoval; Alexandre Ambrogelly; Jesse Rinehart; David Wei; L Rogelio Cruz-Vera; David E Graham; Karl O Stetter; Gabriel Guarneros; Dieter Söll
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-10       Impact factor: 11.205

Review 3.  Mutation in ADORA1 identified as likely cause of early-onset parkinsonism and cognitive dysfunction.

Authors:  Elham Jaberi; Mohammad Rohani; Gholam Ali Shahidi; Shahriar Nafissi; Ehsan Arefian; Masoud Soleimani; Abolfazl Moghadam; Mohsen Karimi Arzenani; Farid Keramatian; Brandy Klotzle; Jian-Bing Fan; Casey Turk; Frank Steemers; Elahe Elahi
Journal:  Mov Disord       Date:  2016-05-02       Impact factor: 10.338

4.  Expression, purification, and buffer solubility optimization of the putative human peptidyl-tRNA hydrolase PTRHD1.

Authors:  Geordan L Burks; Hana McFeeters; Robert L McFeeters
Journal:  Protein Expr Purif       Date:  2016-05-24       Impact factor: 1.650

5.  PTRHD1 and possibly ADORA1 mutations contribute to Parkinsonism with intellectual disability.

Authors:  Elahe Elahi
Journal:  Mov Disord       Date:  2017-11-16       Impact factor: 10.338

6.  PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism.

Authors:  Hamidreza Khodadadi; Luis J Azcona; Vajiheh Aghamollaii; Mir Davood Omrani; Masoud Garshasbi; Shaghayegh Taghavi; Abbas Tafakhori; Gholam Ali Shahidi; Javad Jamshidi; Hossein Darvish; Coro Paisán-Ruiz
Journal:  Mov Disord       Date:  2016-10-18       Impact factor: 10.338

7.  Lack of PTRHD1 mutation in patients with young-onset and familial Parkinson's disease in a Taiwanese population.

Authors:  Szu-Ju Chen; Chang-Han Ho; Hang-Yi Lin; Chin-Hsien Lin; Ruey-Meei Wu
Journal:  Neurobiol Aging       Date:  2020-09-08       Impact factor: 4.673

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.